ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov019

Hybrid Nano-Bio Platforms: Synergistic Strategies Combining Probiotic Metabolites and Nanocarriers Against Multidrug-Resistant Pathogens

Dwaipayan Hor[1]; Rajendra Chouksey[1]; Soumen Dey[1]; Priya Barman[1]; Abul Hasnat[2]

[1]Department of Pharmacy, Sanaka Educational Trust's Group of Institutions, Maulana Abul Kalam Azad University of Technology, West Bengal, India
[2]Department of Pharmacy, Nabadiganta College of Education, West Bengal State Council of Technical & Vocational Education and Skill Development, West Bengal, India

Publication Date: 2025/11/08

Abstract: Multidrug-resistant (MDR) bacterial infections are becoming more common, which is a serious global health concern that calls for innovative antimicrobial approaches that go beyond traditional antibiotic treatments. In order to improve antibacterial efficacy, this review carefully investigates hybrid nano-bio platforms that combine probiotic-derived metabolites with nanoscale delivery technologies in a synergistic manner. Despite having natural antibacterial, antibiofilm, and immunomodulatory properties, probiotic metabolites such as bacteriocins, biosurfactants, organic acids, and reuterin are clinically limited because of their poor stability and lack of targeted administration. By enhancing bioavailability, stability, and permitting controlled, stimuli-responsive release, encapsulation within nanocarriers such polymeric nanoparticles, liposomes, solid lipid nanoparticles, and metallic nanostructures overcomes these difficulties. These hybrid systems restore antibiotic sensitivity and increase pathogen clearance by acting through a variety of antibacterial mechanisms, such as membrane rupture, efflux pump inhibition, biofilm penetration, and immunological modulation. Stimuli-responsive designs maximise therapeutic specificity while reducing off-target toxicity by enabling precise drug release in response to microenvironmental cues such as pH changes or oxidative stress. Translational obstacles still exist despite encouraging preclinical studies showing strong and long-lasting antibacterial activities with excellent biocompatibility characteristics. These include issues with thorough safety evaluations, regulatory classification, and scalable production. The development of adaptive, multifunctional, and safe next-generation antimicrobials that can successfully combat MDR pathogens and stop the global antibiotic resistance crisis is made possible by the interdisciplinary integration of microbial biotechnology and nanomedicine, which is embodied in hybrid nano-bio platforms.

Keywords: *Hybrid Nanocarriers, Probiotic Metabolites, Antimicrobial Resistance, Biofilm Inhibition, Bacteriocins, Nanomedicine.*

How to Cite: Dwaipayan Hor; Rajendra Chouksey; Soumen Dey; Priya Barman; Abul Hasnat (2025) Hybrid Nano-Bio Platforms: Synergistic Strategies Combining Probiotic Metabolites and Nanocarriers Against Multidrug-Resistant Pathogens. *International Journal of Innovative Science and Research Technology,* 10(11), 77-84. https://doi.org/10.38124/ijisrt/25nov019

I. INTRODUCTION

One of the most important worldwide health issues of the twenty-first century is the sharp rise in multidrug-resistant (MDR) bacterial infections [1]. Antimicrobial resistance (AMR) is one of the top ten public health problems, according to the World Health Organisation (WHO), which attributes it to the overuse and abuse of antibiotics in the veterinary, clinical, and agricultural sectors [2]. Complex resistance mechanisms, including as biofilm formation, efflux pump activation, and horizontal gene transfer, have been established by MDR bacteria such Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. These adaptive characteristics make traditional antibiotics ineffective, which results in high morbidity, protracted illnesses, and higher global healthcare costs. Research on biogenic approaches—which use naturally existing

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov019

antimicrobial compounds produced from probiotic microorganisms—has increased due to the pressing demand for alternative therapeutic strategies [3,4].

Numerous bioactive metabolites, including as bacteriocins, biosurfactants, organic acids, and reuterin, are produced by probiotic species such Lactobacillus, Bifidobacterium, and Bacillus[5]. Strong antibacterial, antibiofilm, and immunomodulatory properties have been shown for these metabolites. In contrast to conventional antibiotics, they work by creating reactive oxygen species, altering pH, and disrupting membranes, all of which work together to prevent bacterial survival without leading to widespread resistance. However, these chemicals' intrinsic instability, vulnerability to enzymatic degradation, low systemic bioavailability, and brief half-life under physiological conditions pose serious obstacles to their clinical application. An effective delivery method that guarantees stability, targeted action, and long-term therapeutic efficacy is required to meet these challenges[6,7].

The exact encapsulation and protection of labile bioactives within nanoscale carriers made possible by nanotechnology is a promising way to overcome these obstacles [8]. Numerous nanocarrier systems, including metallic nanostructures, liposomes, polymeric nanoparticles, and solid lipid nanoparticles, have shown remarkable promise in enhancing the pharmacokinetic and pharmacodynamic performance of medications. Researchers can create hybrid nano-bio systems with physicochemical stability and biological selectivity by incorporating metabolites from probiotics into nanocarriers. By enabling deep biofilm penetration, regulated drug release, and cooperative interaction with bacterial membranes, these hybrid platforms improve antimicrobial potency. Furthermore, therapeutic precision at infected locations is further enhanced by the capacity to create stimuli-responsive nanocarriers that release payloads in response to environmental cues like pH variations or oxidative stress[9,10].

In addition to their antibacterial effect, hybrid nano-bio systems can influence the host immune response by increasing macrophage activation, enhancing cytokine control, and restoring the normal microbial balance disrupted by infection[11]. Because of their biodegradable and biocompatible makeup, they also show less cytotoxicity than chemical antimicrobials. Despite these benefits, there are still significant barriers to moving these systems from lab research to clinical use, including large-scale manufacturing, standardisation, and regulatory classification. Establishing safe, repeatable, and scalable manufacturing systems necessitates interdisciplinary studies combining pharmacology, materials science, nanotechnology, and microbiology[12,13]. As a result, the creation of hybrid nano-bio platforms is a revolutionary step in the direction of next-generation antibiotic treatment. These systems offer a durable, flexible, and successful method of fighting MDR pathogens and resolving the worldwide antibiotic resistance dilemma by combining the inherent bioactivity of probiotic metabolites with the accuracy of nanocarrier engineering[14,15].

II. CONCEPT AND RATIONALE FOR HYBRID NANO-BIO SYSTEMS

The development of hybrid nano-bio systems, a novel class of antimicrobial platforms that combine biological specificity with nanoscale accuracy, has been made possible by the convergence of microbial biotechnology and nanomedicine[16,17]. The fundamental justification for this strategy is the use of nanocarriers to get beyond the inherent drawbacks of metabolites formed from probiotics, including their instability, quick enzymatic breakdown, and brief systemic half-life. Strong antibacterial qualities are demonstrated by probiotic bioactives such as bacteriocins (like nisin and plantaricin), biosurfactants (like surfactin), and short-chain fatty acids (like acetate and butyrate) against both Gram-positive and Gram-negative pathogens. Their complex mechanism of action includes microbial homeostasis modification, membrane rupture, and biofilm formation inhibition. However, because of pH variations and enzymatic activity, these natural chemicals are frequently destroyed in the physiological milieu, greatly diminishing their therapeutic efficacy[18,19].

By encasing these bioactives in protective matrices that prevent degradation, nanocarriers offer a strong solution that guarantees controlled release and long-lasting therapeutic efficacy[20]. Additionally, these carriers' nanoscale size allow for effective dispersion through bacterial biofilms and cellular barrier penetration—two crucial abilities in the fight against multidrug-resistant (MDR) infections. A promising avenue for next-generation anti-infective therapies is opened by hybrid nano-bio structures, which combine targeted administration, improved stability, and synergistic antimicrobial activity by fusing functional nanoparticles with physiologically active metabolites[21,22].

III. PROBIOTIC METABOLITES: NATURAL ANTIMICROBIAL RESERVOIRS

A diverse range of compounds produced by probiotic microorganisms operate as organic antimicrobials, offering a comprehensive defence against harmful bacteria[23]. These metabolites work in a variety of complimentary ways to produce their effects. Bacteriocins are peptide toxins produced by ribosome synthesis that cause cell lysis by creating holes in bacterial membranes. Because they are amphiphilic molecules, biosurfactants interfere with bacterial adhesion and break down lipid bilayers, which stops colonisation and the formation of biofilms. Lactic, acetic, and butyric acids are examples of organic acids that help by acidifying the surrounding environment and preventing the activity of bacterial enzymes. Furthermore, essential biological components like proteins and DNA are harmed by reactive metabolites like hydrogen peroxide and reuterin[24,25].

In addition to their direct antibacterial activity, these metabolites are essential for preserving gut homeostasis,

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov019

boosting mucosal immunity, and ecologically modulating pathogenic microbes to outcompete them. However, their practical therapeutic usage is limited by issues like non-specific dispersion, uncontrolled deterioration, and poor stability. These drawbacks are addressed by incorporation into nanocarriers, which permits more effective and prolonged distribution, increased bioavailability, and higher resistance to enzymatic degradation. As a result, probiotic metabolites can serve as a powerful and renewable source of antimicrobial agents with clinical translational promise when combined with nanotechnology[26,27].

IV. NANOCARRIER SYSTEMS FOR PROBIOTIC METABOLITE DELIVERY

Based on their therapeutic goal and physicochemical compatibility, a number of nanocarrier systems have been developed to maximise the transport of bioactives produced from probiotics. The protective encapsulation provided by polymeric nanoparticles made of biodegradable polymers like chitosan, alginate, and poly(lactic-co-glycolic acid) (PLGA) inhibits premature breakdown and promotes adherence to mucosal surfaces. Phospholipid or non-ionic surfactant bilayers make up liposomes and niosomes, which effectively encapsulate hydrophilic and lipophilic metabolites while permitting site-specific and prolonged release. By producing reactive oxygen species and disrupting membranes, metallic nanoparticles made with probiotic supernatants—such as silver, zinc oxide, and gold nanostructures—display potent bactericidal action. By providing biocompatibility, a high drug loading capacity, and longer release profiles, solid lipid nanoparticles (SLNs) further improve stability for lipid-soluble metabolites. When combined, these nanocarrier systems serve as the fundamental building blocks of hybrid nano-bio platforms, guaranteeing safe, effective, and synergistic therapeutic action against multidrug-resistant bacteria[28,29].

V. MECHANISTIC SYNERGY IN HYBRID NANO-BIO PLATFORMS

In order to obtain improved antimicrobial effectiveness against resistant bacteria, hybrid nano-bio systems take advantage of the complementing interaction between probiotic-derived metabolites and sophisticated nanocarriers. There are multiple interrelated mechanisms that contribute to this synergy. In order to induce localised release of powerful bacteriocins, which causes significant disruption of bacterial biofilms and improved microbial eradication, nanocarriers first enable deep penetration into bacterial biofilms, which are protective matrices that are known to safeguard MDR bacteria. Probiotic-produced biosurfactants efficiently destabilise bacterial membranes when they are conjugated to or enclosed within nanocarriers. In addition to directly impairing microbial integrity, this action also makes the bacteria more permeable, which enhances the cellular uptake and local concentration of therapeutic medicines[30,31].

The suppression of bacterial efflux pumps by metabolite–nanocarrier complexes is an important mechanistic characteristic. Hybrid platforms increase antibacterial activity by limiting the evacuation of both bioactives and conventional medications and restoring antibiotic sensitivity by blocking these active transport mechanisms. Furthermore, some probiotic metabolites that are incorporated into nanobio systems have the ability to alter host immune responses. An environment where both innate and adaptive immunity are optimised for infection management is created by increased neutrophil and macrophage activity, which helps to clear pathogens more effectively. When taken together, these pathways demonstrate the strong and diverse antibacterial synergy achieved in hybrid nano-bio structures[32].



Fig 1 Mechanistic Synergy of Hybrid Nano-Bio Platforms: Nanocarriers Penetrate Bacterial Biofilms and Locally Release Probiotic-Derived Bacteriocins, while Biosurfactants Disrupt Cell Membranes. The Platform Further Inhibits Bacterial Efflux Pumps and Modulates Immune Responses, Resulting in Amplified and Multifaceted Antimicrobial Activity Against Multidrug-Resistant Pathogens [33,34,35].

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov019

VI. IN VITRO AND IN VIVO EVIDENCE

The exceptional effectiveness and safety profile of hybrid nano-bio systems are confirmed by an increasing amount of experimental research. An important turning point in the development of antibiofilm strategies has been reached when in vitro tests clearly show that chitosan nanoparticles loaded with nisin can reduce Staphylococcus aureus biofilm biomass by up to 80%. Surfactin-functionalized silver nanoparticles have demonstrated dual-mode activity, addressing both planktonic and sessile bacterial communities with strong antibacterial effects and noticeable biofilm destruction. Additionally, when liposomes containing metabolites like retin are challenged against Escherichia coli, they increase the stability of their payloads and prolong antibacterial efficacy[9,36].

Table 1 Representative Hybrid Nano-Bio Systems and their Antimicrobial Performance [37,38,39]

Hybrid System	Probiotic Metabolite	Nanocarrier Type	Target Pathogen	Mechanism	Key Outcome
Nisin–Chitosan NP	Bacteriocin (Nisin)	Polymeric NP	S. aureus	Biofilm inhibition	80% biomass reduction
Surfactin–AgNP	Biosurfactant (Surfactin)	Silver NP	P. aeruginosa	Membrane disruption	Enhanced bacterial kill
Reuterin–Liposome	Aldehyde (Reuterin)	Liposome	E. coli	ROS-mediated damage	3× prolonged effect
Lactic Acid–SLN	Organic acid	Lipid NP	A. baumannii	pH-dependent release	70% CFU reduction

VII. STIMULI-RESPONSIVE HYBRID SYSTEMS

The exact construction of hybrid nano-bio systems that may release antimicrobial drugs selectively in response to particular disease-associated triggers has been made possible by recent developments in nanomedicine. Because their release patterns may be adjusted to occur at the place and time of infection, these stimuli-responsive nanocarriers provide important benefits in targeted antimicrobial therapy. For instance, pH-sensitive carriers are designed to stay stable in physiologically normal settings but quickly release their payload in the acidic environments seen in tissues that are inflamed or sick. This tactic lowers systemic toxicity while increasing local medication concentration[40].

Another novel kind of nanocarriers are enzyme-responsive ones, which contain cleavable bonds or coatings that react to high concentrations of bacterial enzymes like β-lactamases. The nanocarriers' structural alterations in response to these enzymes cause the site-specific release of antibacterial substances in diseased areas. Furthermore, ROS-sensitive nanocarriers, which are triggered in response to elevated reactive oxygen species, can be used to take advantage of the particular oxidative stress found at infection foci. This ensures that treatments are delivered primarily within pathogenic microenvironments, adding another degree of specificity. Together, these intelligent systems optimise the therapeutic index and reduce off-target effects, opening the door to safer and more potent antibacterial therapies[41,42].



Fig 2 Stimuli-Responsive Antimicrobial Nanocarriers: Schematic Illustration of pH-, Enzyme-, and ROS-Responsive Nanocarriers Releasing Antimicrobial Agents in Infection Microenvironments [43,44,45].

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov019

VIII. BIOCOMPATIBILITY AND SAFETY CONSIDERATIONS

The creation of hybrid nano-bio systems that are clinically viable requires close consideration of biocompatibility and safety[46,47]. Building nanocarriers with biodegradable polymers and naturally occurring materials reduces the possibility of long-term tissue buildup by ensuring that the carriers are effectively metabolised or eliminated. A positive safety profile is further supported by the incorporation of biocompatible probiotic metabolites. However, in order to assess potential dangers, thorough pharmacokinetic studies and histopathological analyses are necessary, especially when dealing with metallic nanoparticles, which, if not well managed, may show dose-dependent cytotoxicity and oxidative side effects[48]. To ensure that these cutting-edge systems provide strong antibacterial action without endangering patient safety, systematic evaluation of biodistribution, clearance, and cumulative toxicity is still necessary for successful clinical translation[49,50].

Table 2 Advantages and Limitations of Hybrid Nano-Bio Platforms [51,52,53]

Aspect	Advantages	Limitations
Efficacy	Enhanced antibiofilm and antibacterial activity	Limited long-term in vivo data
Safety	Biodegradable and biocompatible	Metal-based systems may induce ROS toxicity
Production	Green synthesis feasible	Scale-up challenges
Regulation	Natural components simplify approval	Complex hybrid classification

IX. DISCUSSION

The effectiveness of traditional antibiotic treatments is called into question by the growth of multidrug-resistant (MDR) bacterial infections, underscoring the pressing need for novel therapeutic approaches. One intriguing approach to resolving these issues is the use of hybrid nano-bio platforms, which combine sophisticated nanocarrier systems with metabolites produced from probiotics. By encapsulating probiotic metabolites including bacteriocins, biosurfactants, and organic acids in nanocarriers, these platforms improve their stability, targeting, and controlled release while utilising their inherent antibacterial qualities[54,55].

Encapsulation greatly increases the bioavailability of these bioactives by shielding them from harsh microenvironments and physiological enzymes that would otherwise break them down too quickly. By entering bacterial biofilms and overcoming cellular barriers—two important defence mechanisms used by MDR pathogens—nanocarriers enable targeted delivery. Stimuli-responsive devices, which induce payload release in geographically and temporally controlled ways when they come into contact with infection-specific triggers such as increased reactive oxygen species (ROS), bacterial enzymes, or acidic pH, further enhance this targeting. The therapeutic efficacy is enhanced and systemic toxicity is decreased by this focused release[56,57].

In addition to their direct antibacterial action, hybrid nano-bio platforms enhance pathogen clearance by influencing the host immune response through the stimulation of important immune cells including neutrophils and macrophages. Utilising these platforms, experimental research has shown significant antibiofilm efficacy, decreased bacterial burden, and enhanced longevity in animal models[58].

However, there are still issues with clinical translation. Optimisation is necessary to scale up the manufacturing of consistent, biocompatible nanocarriers. Furthermore, safety assessments are essential, particularly for metallic nanoparticles, which could present issues with oxidative stress and long-term accumulation. To guarantee patient safety, thorough pharmacokinetic and toxicological investigations are required[59].

In conclusion, by fusing biological specificity with nanotechnological precision, hybrid nano-bio systems provide a flexible and successful defence against MDR infections. Their continued advancement has great potential to alleviate the worldwide problem of antibiotic resistance[60,61].

X. ACKNOWLEDGEMENT

We would like to acknowledge Department of Pharmacy, Sanaka Educational Trust's Group of Institutions, Maulana Abul Kalam Azad University of Technology, West Bengal, India for encouragement and support.

- Competing Interests: Nil

XI. CONCLUSION

A revolutionary advancement in the battle against bacterial infections that are resistant to several drugs is represented by hybrid nano-bio systems. These systems offer a number of benefits by utilising the special combination of biologically active probiotic metabolites and carefully designed nanocarriers. These benefits include avoiding traditional resistance mechanisms, delivering stimuli-responsive and site-specific drug release, and improving patient safety and antimicrobial efficacy. They are extremely adaptable tools for next-generation infection control because of their capacity to break up biofilms, alter immune responses, and adjust to the localised microenvironment. However, resolving present issues with large-scale production, safety validation, and regulatory approval is necessary to realise these hybrid systems' full clinical promise. Their successful translation will depend on

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov019

advancements in materials science, meticulous biocompatibility assessment, and high-fidelity characterisation. The well-planned fusion of pharmacology, nanotechnology, and microbiology is set to produce novel, long-lasting remedies for antibiotic resistance as interdisciplinary cooperation develops. In the end, hybrid nano-bio systems represent a paradigm change that goes beyond conventional antibiotics and makes it possible to create tailored, efficient, and adaptable antimicrobial treatments for a time when resistant infections are a threat.

REFERENCES

[1]. Mba IE, Nweze EI. Nanoparticles as therapeutic options for treating multidrug-resistant bacteria: research progress, challenges, and prospects. World Journal of Microbiology and Biotechnology. 2021 Jun;37(6):108.

[2]. Talebi Bezmin Abadi A, Rizvanov AA, Haertlé T, Blatt NL. World Health Organization report: current crisis of antibiotic resistance. BioNanoScience. 2019 Dec;9(4):778-88.

[3]. Machado A, Zamora-Mendoza L, Alexis F, Álvarez-Suarez JM. Use of plant extracts, bee-derived products, and probiotic-related applications to fight multidrug-resistant pathogens in the post-antibiotic era. Future Pharmacology. 2023 Jul 4;3(3):535-67.

[4]. Abouelela ME, Helmy YA. Next-generation probiotics as novel therapeutics for improving human health: current trends and future perspectives. Microorganisms. 2024 Feb 20;12(3):430.

[5]. Chugh B, Kamal-Eldin A. Bioactive compounds produced by probiotics in food products. Current opinion in food science. 2020 Apr 1;32:76-82.

[6]. Singh AP, Biswas A, Shukla A, Maiti P. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal transduction and targeted therapy. 2019 Aug 30;4(1):33.

[7]. Saini P, Chakraborty T, Jain A, Saini V "Taste masking of Bitter Drug in Suspension: An overview" International Journal of Pharmaceutical Sciences Letters 2013 Vol. 3 (4) Page 229-237.

[8]. Bazana MT, Codevilla CF, de Menezes CR. Nanoencapsulation of bioactive compounds: Challenges and perspectives. Current opinion in food science. 2019 Apr 1;26:47-56.

[9]. Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert opinion on drug delivery. 2021 Feb 1;18(2):205-27.

[10]. Kumar A, Goyal K, Ullah SN, Jindal S. Stimuli responsive nanotechnological advancements in infectious disorders. InNanostructured Drug Delivery Systems in Infectious Disease Treatment 2024 Jan 1 (pp. 83-101). Academic Press.

[11]. Rawat N, Ahmad N, Raturi P, Singhvi N, Sahai N, Kothiyal P. Nanobiomaterials: exploring mechanistic roles in combating microbial infections and cancer. Discover Nano. 2023 Dec 20;18(1):158.

[12]. Yadav A, Thakur P, Thakur A, Suhag D. Challenges in Scaling Nanobiology for Clinical Use. InAdvancements in Nanobiology 2025 Mar 25 (pp. 303-317). CRC Press.

[13]. Chakraborty T, Saini V, Singh G , Govila D and Pandurangan A "Causes and Management of Major Microbial Infections in Upper Sensory Organs of the Body" International Journal of Pharmaceutical Sciences Review and Research, 2018, 48(1):43-51.

[14]. Rajkhowa S, Hussain SZ, Agarwal M, Zaheen A, Al-Hussain SA, Zaki ME. Advancing Antibiotic-Resistant Microbe Combat: Nanocarrier-Based Systems in Combination Therapy Targeting Quorum Sensing. Pharmaceutics. 2024 Sep 3;16(9):1160.

[15]. Chen A, Gong Y, Wu S, Du Y, Liu Z, Jiang Y, Li J, Miao YB. Navigating a challenging path: precision disease treatment with tailored oral nano-armor-probiotics. Journal of Nanobiotechnology. 2025 Feb 1;23(1):72.

[16]. Shahcheraghi N, Golchin H, Sadri Z, Tabari Y, Borhanifar F, Makani S. Nano-biotechnology, an applicable approach for sustainable future. 3 Biotech. 2022 Mar;12(3):65.

[17]. Rathore R, Yadav A. Bio-nanotechnology in Cancer Research. InAdvancements in Nanobiology 2025 Mar 25 (pp. 215-234). CRC Press.

[18]. Thapa S, Li H, OHair J, Bhatti S, Chen FC, Nasr KA, Johnson T, Zhou S. Biochemical characteristics of microbial enzymes and their significance from industrial perspectives. Molecular biotechnology. 2019 Aug 1;61(8):579-601.

[19]. Percival SL, McCarty S, Hunt JA, Woods EJ. The effects of pH on wound healing, biofilms, and antimicrobial efficacy. Wound repair and regeneration. 2014 Mar;22(2):174-86.

[20]. Bernardes BG, Veiga A, Barros J, García-González CA, Oliveira AL. Sustainable silk-based particulate systems for the controlled release of pharmaceuticals and bioactive agents in wound healing and skin regeneration. International Journal of Molecular Sciences. 2024 Mar 8;25(6):3133.

[21]. Li X, Peng X, Zoulikha M, Boafo GF, Magar KT, Ju Y, He W. Multifunctional nanoparticle-mediated combining therapy for human diseases. Signal Transduction and Targeted Therapy. 2024 Jan 1;9(1):1.

[22]. Mallick MA, Chakraborty T et.al "Schematic diagrammatic preparation methods of polymeric nanoparticles for biomedical applications in recent and future prospects" European Chemical Bulletin , 2023,12(10):1721-1733

[23]. Monika K, Malik T, Gehlot R, Rekha K, Kumari A, Sindhu R, Rohilla P. Antimicrobial property of probiotics. Environment Conservation Journal. 2021 Mar 8;22(SE):33-48.

[24]. Basu Thakur P, Long AR, Nelson BJ, Kumar R, Rosenberg AF, Gray MJ. Complex responses to hydrogen peroxide and hypochlorous acid by the probiotic bacterium Lactobacillus reuteri. Msystems. 2019 Oct 29;4(5):10-128.

[25]. Thakur PB, Long AR, Nelson BJ, Kumar R, Rosenberg AF, Gray MJ. Complex responses to hydrogen peroxide and hypochlorous acid by the

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov019

probiotic bacterium Lactobacillus reuteri. MSystems. 2019 Sep 3;4(5):e00453-19.

[26]. Umekar M, Chaudhary AA, Manghani M, Shidhaye S, Khajone P, Mahore J, Rudayni HA, Trivedi R. Probiotics in Nanotechnology-Driven Wound Healing: From Mechanistic Insight to Clinical Promise. Pharmaceutics. 2025 Jun 21;17(7):805.

[27]. Srivastava P, Kim KS. Membrane vesicles derived from gut microbiota and probiotics: cutting-edge therapeutic approaches for multidrug-resistant superbugs linked to neurological anomalies. Pharmaceutics. 2022 Nov 3;14(11):2370.

[28]. Hetta HF, Ramadan YN, Al-Harbi AI, A. Ahmed E, Battah B, Abd Ellah NH, Zanetti S, Donadu MG. Nanotechnology as a promising approach to combat multidrug resistant bacteria: a comprehensive review and future perspectives. Biomedicines. 2023 Jan 31;11(2):413.

[29]. Kalia P, Thakur P, Kumar R. Advancing Precision Therapeutics Integrating Microbiota Biomarkers and Nanotechnology for Targeted Drug Delivery: Insights from Case Studies. Microbiota Profiling for Precision Medicine: Biomarker-Targeted Drug Delivery Strategies. 2025 Oct 20:239-80.

[30]. Chakraborty T, Natasha, Saini V, Ruby "Formulation and evaluation of controlled release floating tablets of cefixime using hydrophilic polymers" International Research Journal of Pharmacy, 2019, 10 (1): 171-175.

[31]. Benedetto Tiz D, Kikelj D, Zidar N. Overcoming problems of poor drug penetration into bacteria: challenges and strategies for medicinal chemists. Expert Opinion on Drug Discovery. 2018 Jun 3;13(6):497-507.

[32]. Tiwari AK, Pandey PC, Gupta MK, Narayan RJ. Nano–bio interaction and antibacterial mechanism of engineered metal nanoparticles: fundamentals and current understanding. Journal of Cluster Science. 2025 Feb;36(1):5.

[33]. Barbinta-Patrascu ME, Badea N, Pirvu C, Bacalum M, Ungureanu C, Nadejde PL, Ion C, Rau I. Multifunctional soft hybrid bio-platforms based on nano-silver and natural compounds. Materials Science and Engineering: C. 2016 Dec 1;69:922-32.

[34]. Habeeb M, Vengateswaran HT, Kumbhar ST, You HW, Asane GS, Aher KB. Nano–bio interactions: understanding their dynamic connections. InTheranostics Nanomaterials in Drug Delivery 2025 Jan 1 (pp. 11-25). Academic Press.

[35]. Wang Y, Zhang X, Yue H. Two-dimensional nanomaterials induced nano-bio interfacial effects and biomedical applications in cancer treatment. Journal of Nanobiotechnology. 2024 Feb 18;22(1):67.

[36]. Chakraborty T, Saini V, Narwal P, Gupta S "Formulation and evaluation of both stomach and Intestine drug delivery system from unit solid dosage tablet formulation" World Journal of Pharmaceutical Research, 2015:4(10): 1377-1392.

[37]. Barbinta-Patrascu ME, Badea N, Pirvu C, Bacalum M, Ungureanu C, Nadejde PL, Ion C, Rau I. Multifunctional soft hybrid bio-platforms based on nano-silver and natural compounds. Materials Science and Engineering: C. 2016 Dec 1;69:922-32.

[38]. Mahyad B, Janfaza S, Hosseini ES. Bio-nano hybrid materials based on bacteriorhodopsin: potential applications and future strategies. Advances in colloid and interface science. 2015 Nov 1;225:194-202.

[39]. Ivanova K, Ivanova A, Hoyo J, Pérez-Rafael S, Tzanov T. Nano-formulation endows quorum quenching enzyme-antibiotic hybrids with improved antibacterial and antibiofilm activities against Pseudomonas aeruginosa. International journal of molecular sciences. 2022 Jul 11;23(14):7632.

[40]. Lipsi K, Pande M. Innovative polymer-based therapeutics targeting inflammation for responsive drug delivery in disease treatment. Inflammopharmacology. 2025 Oct 13:1-7.

[41]. Prajapati RN, Bhushan B, Singh K, Chopra H, Kumar S, Agrawal M, Pathak D, Chanchal DK, Laxmikant. Recent advances in pharmaceutical design: unleashing the potential of novel therapeutics. Current Pharmaceutical Biotechnology. 2024 Dec 1;25(16):2060-77.

[42]. Dey S, Hassan S, Pandey RK. Nanomedicine in targeted drug delivery: precision therapeutics for personalized medicine. InNanomedicine: Innovations, Applications, and Breakthroughs in the Quest for Health and Medicine's Future 2024 Dec 10 (pp. 179-231). Cham: Springer Nature Switzerland.

[43]. Ding M, Zhao W, Song LJ, Luan SF. Stimuli-responsive nanocarriers for bacterial biofilm treatment. Rare Metals. 2022 Feb;41(2):482-98.

[44]. Zhang B, Lu D, Duan H. Recent advances in responsive antibacterial materials: design and application scenarios. Biomaterials Science. 2023;11(2):356-79.

[45]. Wu JM, Liu Y, Han HY, Song ZY. Recent advances in endogenous and exogenous stimuli-responsive nanoplatforms for bacterial infection treatment. Biomed. Eng. Commun. 2023;2(1):2-3.

[46]. Ricotti L, Cafarelli A, Iacovacci V, Vannozzi L, Menciassi A. Advanced micro-nano-bio systems for future targeted therapies. Current Nanoscience. 2015 Apr 1;11(2):144-60.

[47]. Waheed S, Li Z, Zhang F, Chiarini A, Armato U, Wu J. Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. Journal of Nanobiotechnology. 2022 Aug 31;20(1):395.

[48]. Saifi MA, Khan W, Godugu C. Cytotoxicity of nanomaterials: Using nanotoxicology to address the safety concerns of nanoparticles. Pharmaceutical nanotechnology. 2018 Mar 1;6(1):3-16.

[49]. Saini V, Chakraborty T, Jain A, Chaudhary J, Saini V "Comparative Study of Resins in the Formulation of Taste Masked Suspension of Erythromycin" Int. J.Pharm. Sci. Rev. Res.,2013, 22(1): 257-263

[50]. Shahiwala A. Advancing drug delivery research: sustainable strategies for innovation and translation.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov019

Drug Delivery and Translational Research. 2025 May;15(5):1513-24.

[51]. Mahyad B, Janfaza S, Hosseini ES. Bio-nano hybrid materials based on bacteriorhodopsin: potential applications and future strategies. Advances in colloid and interface science. 2015 Nov 1;225:194-202.

[52]. Barbinta-Patrascu ME, Badea N, Pirvu C, Bacalum M, Ungureanu C, Nadejde PL, Ion C, Rau I. Multifunctional soft hybrid bio-platforms based on nano-silver and natural compounds. Materials Science and Engineering: C. 2016 Dec 1;69:922-32.

[53]. Shahcheraghi N, Golchin H, Sadri Z, Tabari Y, Borhanifar F, Makani S. Nano-biotechnology, an applicable approach for sustainable future. 3 Biotech. 2022 Mar;12(3):65.

[54]. Mohanty D, Suar M, Panda SK. Nanotechnological interventions in bacteriocin formulations–advances, and scope for challenging food spoilage bacteria and drug-resistant foodborne pathogens. Critical Reviews in Food Science and Nutrition. 2025 Feb 25;65(6):1126-43.

[55]. Sidhu PK, Nehra K. Bacteriocin-nanoconjugates as emerging compounds for enhancing antimicrobial activity of bacteriocins. Journal of King Saud University-Science. 2019 Oct 1;31(4):758-67.

[56]. Chakraborty T, Saini V, Sharma S, Kaur B, Dhingra G "Antifungal gel; for different routes of administration and different drug delivery system" International Journal of Biopharmaceutics, 2014, 5(3): 230-240

[57]. Lin Z, Gao W, Hu H, Ma K, He B, Dai W, Wang X, Wang J, Zhang X, Zhang Q. Novel thermo-sensitive hydrogel system with paclitaxel nanocrystals: High drug-loading, sustained drug release and extended local retention guaranteeing better efficacy and lower toxicity. Journal of Controlled Release. 2014 Jan 28;174:161-70.

[58]. Li J, Cheung WH, Chow SK, Ip M, Leung SY, Wong RM. Current therapeutic interventions combating biofilm-related infections in orthopaedics: a systematic review of in vivo animal studies. Bone & Joint Research. 2022 Oct 4;11(10):700-14.

[59]. Borgert CJ, Fuentes C, Burgoon LD. Principles of dose-setting in toxicology studies: the importance of kinetics for ensuring human safety. Archives of Toxicology. 2021 Dec;95(12):3651-64.

[60]. Chinemerem Nwobodo D, Ugwu MC, Oliseloke Anie C, Al-Ouqaili MT, Chinedu Ikem J, Victor Chigozie U, Saki M. Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace. Journal of clinical laboratory analysis. 2022 Sep;36(9):e24655.

[61]. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C. Antibiotic resistance—the need for global solutions. The Lancet infectious diseases. 2013 Dec 1;13(12):1057-98.